Tag:
Tim Anderson
Latest Headlines
Latest Headlines
FDA rejects blockbuster Eliquis bid, asks Pfizer, BMS for trial clarification
Bristol-Myers Squibb and Pfizer have hit another costly snag in their quest to gain an FDA approval for Eliquis (apixaban), their blockbuster anti-clotting hopeful.
Analyst gloomy on Merck trends
An influential pharma analyst downgraded Merck shares, saying they've hit their price ceiling. Why? The reasons can be summed up in four drugs: Singulair, Gardasil, taranabant, and Vytorin. Sanford
Rumor mill: BMS positioning itself for sale
Speculation that Bristol-Myers Squibb might be a takeover target -- that's old news. Informed speculation based on certain strategic moves BMS has made recently -- worth passing on. Tim Anderson, the
